In contrast, administration of zVAD, a pan caspase inhibitor (or anti-FasL antibody) initiated at day 7 after T. cruzi infection was shown to reduce T cell death, promotes type 1 immune response and reduced parasitemia. This evidence concerns the gene FASLG and parasitic infectious disease.